Chitra M Hosing

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7376760/publications.pdf

Version: 2024-02-01

354 papers	15,614 citations	20797 60 h-index	20943 115 g-index
355 all docs	355 docs citations	355 times ranked	13414 citing authors

#	Article	IF	Citations
1	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	13.9	1,252
2	Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 2009, 113, 5720-5726.	0.6	697
3	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 2017, 25, 285-295.	3.7	498
4	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 2013, 122, 2965-2973.	0.6	470
5	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. Journal of Clinical Oncology, 2013, 31, 4199-4206.	0.8	433
6	Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture. New England Journal of Medicine, 2012, 367, 2305-2315.	13.9	430
7	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine, 2018, 378, 35-47.	13.9	417
8	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation, 2016, 126, 3363-3376.	3.9	399
9	Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biology of Blood and Marrow Transplantation, 2014, 20, 295-308.	2.0	305
10	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 2008, 111, 5530-5536.	0.6	294
11	Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 2006, 107, 3074-3080.	0.6	265
12	Tumor necrosis factor-Î± blockade for the treatment of acute GVHD. Blood, 2004, 104, 649-654.	0.6	253
13	Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplantation, 2008, 41, 771-778.	1.3	233
14	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1835-1844.	2.0	227
15	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigenâ€“Matched Unrelated and Related Donors. Biology of Blood and Marrow Transplantation, 2014, 20, 1975-1981.	2.0	207
16	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood, 2009, 113, 4144-4152.	0.6	196
17	Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 178-185.	2.0	192
18	Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. British Journal of Haematology, 2005, 130, 409-417.	1.2	184

#	Article	IF	Citations
19	Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood, 2003, 102, 3052-3059.	0.6	167
20	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology, 2017, 177, 457-466.	1.2	158
21	Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2003, 122, 128-134.	1.2	157
22	Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2009, 15, 718-723.	2.0	150
23	Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and SÃ©zary Syndrome. Journal of Clinical Oncology, 2010, 28, 2365-2372.	0.8	149
24	Steroid-Refractory Acute GVHD: Predictors and Outcomes. Advances in Hematology, 2011, 2011, 1-8.	0.6	146
25	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 2003, 102, 3829-3836.	0.6	143
26	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 2008, 93, 257-264.	1.7	141
27	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer, 2007, 109, 2481-2489.	2.0	138
28	Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkinâ€™s Lymphomas. Journal of Clinical Oncology, 2005, 23, 2240-2247.	0.8	127
29	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. Journal of Antimicrobial Chemotherapy, 2013, 68, 1872-1880.	1.3	125
30	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances, 2020, 4, 5580-5588.	2.5	122
31	Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology, 2004, 32, 28-35.	0.2	119
32	Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood, 2015, 125, 2885-2892.	0.6	118
33	Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan. Biology of Blood and Marrow Transplantation, 2007, 13, 454-462.	2.0	117
34	Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplantation, 2007, 40, 125-136.	1.3	117
35	Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation, 2005, 35, 943-951.	1.3	113
36	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood, 2014, 123, 3263-3268.	0.6	110

#	Article	IF	Citations
37	Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 108-114.	2.0	109
38	Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation. Journal of Clinical Oncology, 2004, 22, 2419-2423.	0.8	106
39	The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood, 2012, 119, 2738-2745.	0.6	106
40	A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2009, 15, 1555-1562.	2.0	104
41	Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood, 2007, 109, 2751-2758.	0.6	98
42	Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 2012, 119, 6373-6378.	0.6	97
43	Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American Journal of Hematology, 2009, 84, 335-337.	2.0	93
44	Clofarabine Â± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biology of Blood and Marrow Transplantation, 2011, 17, 893-900.	2.0	93
45	Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biology of Blood and Marrow Transplantation, 2011, 17, 1490-1496.	2.0	90
46	Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Annals of Oncology, 2015, 26, 2490-2495.	0.6	87
47	Detection and Control of a Nosocomial Respiratory Syncytial Virus Outbreak in a Stem Cell Transplantation Unit: The Role of Palivizumab. Biology of Blood and Marrow Transplantation, 2010, 16, 1265-1271.	2.0	81
48	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood, 2016, 128, 1346-1361.	0.6	81
49	The survival outcome of patients with relapsed/refractory peripheral Tâ€cell lymphomaâ€not otherwise specified and angioimmunoblastic Tâ€cell lymphoma. British Journal of Haematology, 2017, 176, 750-758.	1.2	78
50	Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood, 2009, 114, 2884-2887.	0.6	76
51	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Translational Medicine, 2014, 3, 1435-1443.	1.6	75
52	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer, 2016, 122, 3316-3326.	2.0	75
53	Feasibility of autologous hematopoietic stem cell transplant in patients aged â‰¥70 years with multiple myeloma. Leukemia and Lymphoma, 2012, 53, 118-122.	0.6	74
54	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 2006, 106, 1084-1089.	2.0	69

#	Article	IF	Citations
55	Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease: Does It Work?. Biology of Blood and Marrow Transplantation, 2006, 12, 37-40.	2.0	68
56	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2009, 15, 812-816.	2.0	68
57	Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. Biology of Blood and Marrow Transplantation, 2016, 22, 542-548.	2.0	68
58	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e266-e275.	2.2	68
59	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. Journal of Rheumatology, 2013, 40, 455-460.	1.0	67
60	Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1059-1064.	2.0	65
61	Transplant-Associated Microangiopathy in Patients Receiving Tacrolimus Following Allogeneic Stem Cell Transplantation: Risk Factors and Response to Treatment. Biology of Blood and Marrow Transplantation, 2007, 13, 469-477.	2.0	64
62	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British Journal of Haematology, 2015, 168, 646-653.	1.2	64
63	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1232-1236.	2.0	64
64	Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplantation, 2002, 30, 543-546.	1.3	63
65	Incidence and natural history of pure red cell aplasia in major <scp>ABO</scp>â€mismatched haematopoietic cell transplantation. British Journal of Haematology, 2013, 160, 798-805.	1.2	63
66	Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkinâ€™s lymphoma. Annals of Oncology, 2002, 13, 450-459.	0.6	62
67	Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplantation, 2005, 36, 157-162.	1.3	62
68	Autologous Stem Cell Transplantation for Refractory orÂPoor-Risk Relapsed Hodgkin's Lymphoma: Effect of theÂSpecific High-Dose Chemotherapy Regimen onÂOutcome. Biology of Blood and Marrow Transplantation, 2013, 19, 410-417.	2.0	61
69	Postâ€transplantation cyclophosphamide versus conventional graftâ€versusâ€host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology, 2016, 173, 444-455.	1.2	61
70	Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. Journal of Immunotherapy, 2010, 33, 684-696.	1.2	58
71	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forÂPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 47-53.	2.0	58
72	Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia, 2008, 22, 258-264.	3.3	57

#	Article	IF	Citations
73	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 319-326.	0.2	55
74	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood, 2016, 128, 297-312.	0.6	54
75	Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood, 2007, 110, 3456-3462.	0.6	53
76	Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia, 2007, 21, 2540-2544.	3.3	53
77	An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2012, 206, 1367-1371.	1.9	52
78	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1284-1290.	2.0	51
79	Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplantation, 2013, 48, 666-670.	1.3	50
80	Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Frontiers in Medicine, 2015, 2, 89.	1.2	50
81	Double epigenetic modulation of highâ€dose chemotherapy with azacitidine and vorinostat for patients with refractory or poorâ€risk relapsed lymphoma. Cancer, 2016, 122, 2680-2688.	2.0	48
82	Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. British Journal of Haematology, 2006, 133, 533-537.	1.2	47
83	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. Biology of Blood and Marrow Transplantation, 2010, 16, 555-559.	2.0	46
84	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation, 2015, 21, 1914-1920.	2.0	46
85	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2016, 22, 1440-1448.	2.0	44
86	High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Annals of Oncology, 2008, 19, 1166-1171.	0.6	43
87	Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica, 2009, 94, 249-257.	1.7	43
88	Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1819-1826.	2.0	43
89	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1677-1686.	2.0	43
90	West Nile Encephalitis in 2 Hematopoietic Stem Cell Transplant Recipients: Case Series and Literature Review. Clinical Infectious Diseases, 2003, 37, 1044-1049.	2.9	41

#	Article	IF	Citations
91	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplantation, 2007, 39, 279-283.	1.3	41
92	Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplantation, 2008, 42, 67-69.	1.3	41
93	Eculizumab for transplantâ€associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. European Journal of Haematology, 2018, 101, 389-398.	1.1	41
94	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biology of Blood and Marrow Transplantation, 2007, 13, 1066-1072.	2.0	40
95	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 412-420.	2.0	40
96	Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplantation, 2006, 38, 421-426.	1.3	39
97	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biology of Blood and Marrow Transplantation, 2008, 14, 1401-1407.	2.0	39
98	A randomized phase 2 trial of a preparative regimen of bortezomib, highâ€dose melphalan, arsenic trioxide, and ascorbic acid. Cancer, 2012, 118, 2507-2515.	2.0	39
99	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood, 2020, 135, 449-452.	0.6	39
100	Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplantation, 2013, 48, 1218-1223.	1.3	38
101	Outcomes of Haploidentical Stem Cell Transplantation forÂLymphoma with Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 493-498.	2.0	38
102	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. Biology of Blood and Marrow Transplantation, 2009, 15, 1265-1270.	2.0	37
103	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants inÂPatients With SÃ©zary Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e83-e93.	0.2	37
104	High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 991-994.	2.0	36
105	Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the Î²2-adrenergic receptor. Brain, Behavior, and Immunity, 2018, 68, 66-75.	2.0	36
106	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 906-912.	2.0	35
107	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clinical Cancer Research, 2018, 24, 3845-3856.	3.2	35
108	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1227-1232.	2.0	34

#	Article	IF	Citations
109	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 2166-2171.	2.0	34
110	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 1122-1129.	2.0	33
111	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica, 2015, 100, 1361-1370.	1.7	32
112	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Journal of Clinical Oncology, 2021, 39, 2710-2719.	0.8	32
113	Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. Journal of Clinical Oncology, 2011, 29, 294-302.	0.8	31
114	Phase 2 study of lowâ€dose clofarabine plus cytarabine for patients with higherâ€risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer, 2017, 123, 629-637.	2.0	31
115	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 472-476.	0.2	28
116	Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. Journal of Clinical Oncology, 2015, 33, 1557-1563.	0.8	27
117	High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. American Journal of Hematology, 2011, 86, 954-956.	2.0	26
118	Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplantation, 2012, 47, 212-216.	1.3	26
119	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2159-2164.	2.0	26
120	Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large Bâ€cell lymphoma treated with autologous stem cell transplantation. British Journal of Haematology, 2008, 142, 786-792.	1.2	25
121	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. American Journal of Hematology, 2012, 87, 272-276.	2.0	25
122	Peripheral blood stem cell yield calculated using preapheresis absolute <scp>CD</scp>34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion, 2014, 54, 1081-1087.	0.8	25
123	Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. Cancer, 2017, 123, 2329-2337.	2.0	25
124	Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 686-694.	2.0	24
125	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biology of Blood and Marrow Transplantation, 2017, 23, 285-292.	2.0	24
126	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 601-606.	1.3	24

#	Article	IF	Citations
127	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2019, 54, 839-848.	1.3	24
128	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematology,the, 2018, 5, e532-e542.	2.2	23
129	Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. American Journal of Hematology, 2005, 80, 43-45.	2.0	22
130	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leukemia and Lymphoma, 2012, 53, 1239-1241.	0.6	22
131	Justâ€inâ€time rescue plerixafor in combination with chemotherapy and granulocyteâ€colony stimulating factor for peripheral blood progenitor cell mobilization. American Journal of Hematology, 2013, 88, 754-757.	2.0	22
132	Ex Vivo Mesenchymal Precursor Cellâ€“Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation, 2017, 23, 1359-1366.	2.0	22
133	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2197-2203.	2.0	22
134	Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States. Biology of Blood and Marrow Transplantation, 2011, 17, 674-681.	2.0	21
135	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e1-e5.	0.2	21
136	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 665-671.	2.0	21
137	Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Advances, 2018, 2, 2254-2261.	2.5	21
138	Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leukemia and Lymphoma, 2012, 53, 901-906.	0.6	20
139	Augmentation of Blood Dendritic Cells by Extracorporeal Photopheresis in Patients with Leukemic Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2013, 133, 2098-2100.	0.3	20
140	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. American Journal of Hematology, 2019, 94, 1382-1387.	2.0	20
141	Hematopoietic Stem Cell Mobilization with G-CSF. , 2012, 904, 37-47.		19
142	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem CellÂTransplantation for Relapsed and Refractory HodgkinÂLymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1333-1337.	2.0	19
143	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplantation, 2022, 57, 51-56.	1.3	19
144	Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion, 2011, 51, 1300-1313.	0.8	18

#	Article	IF	Citations
145	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1453-1458.	2.0	18
146	False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. Diagnostic Microbiology and Infectious Disease, 2017, 88, 305-307.	0.8	18
147	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. European Journal of Haematology, 2017, 99, 532-535.	1.1	18
148	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplantation and Cellular Therapy, 2021, 27, 430.e1-430.e7.	0.6	18
149	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplantation, 2021, 56, 1316-1324.	1.3	18
150	Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2011, 17, S63-S70.	2.0	17
151	Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2011, 17, 1841-1845.	2.0	17
152	CARs in Chronic Lymphocytic Leukemia â€“ Ready to Drive. Current Hematologic Malignancy Reports, 2013, 8, 60-70.	1.2	17
153	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2016, 57, 1607-1615.	0.6	17
154	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e41-e50.	0.2	17
155	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 1439-1445.	2.0	17
156	Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning withÂFludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1094-1099.	2.0	16
157	Long-Term Outcomes after Treatment with Clofarabineâ€‰Â±â€‰Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1792-1800.	2.0	16
158	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. American Journal of Hematology, 2016, 91, E442-7.	2.0	16
159	Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Frontiers in Immunology, 2018, 9, 2444.	2.2	16
160	Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget, 2016, 7, 63829-63838.	0.8	16
161	High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2006, 47, 1290-1294.	0.6	15
162	Topical cidofovirâ€“induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections. Journal of Oncology Pharmacy Practice, 2016, 22, 325-331.	0.5	15

#	Article	IF	Citations
163	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation, 2016, 22, 961-965.	2.0	15
164	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 1602-1609.	2.0	15
165	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1146-1154.	0.4	15
166	A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica, 2018, 103, e416-e418.	1.7	15
167	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leukemia and Lymphoma, 2019, 60, 442-452.	0.6	15
168	Approaching treatment of transplantâ€associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus. Transfusion, 2019, 59, 3519-3524.	0.8	15
169	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 505-514.	2.0	15
170	A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). Blood, 2020, 136, 40-41.	0.6	15
171	Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 393-394.	1.3	14
172	Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplantation, 2013, 48, 26-31.	1.3	14
173	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 581-587.	2.0	14
174	Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Annals of the American Thoracic Society, 2020, 17, 1329-1333.	1.5	14
175	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 2021, 27, 689-695.	0.6	14
176	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2006, 108, 315-315.	0.6	14
177	Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. American Journal of Infection Control, 2014, 42, 1084-1088.	1.1	13
178	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica, 2021, 106, 3211-3214.	1.7	13
179	Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood, 2008, 112, 154-154.	0.6	13
180	Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leukemia and Lymphoma, 2015, 56, 533-535.	0.6	12

#	Article	IF	Citations
181	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 122-128.	0.2	12
182	A randomized phase <scp>II</scp> study of standardâ€dose versus highâ€dose rituximab with <scp>BEAM</scp> in autologous stem cell transplantation for relapsed aggressive Bâ€cell nonâ€hodgkin lymphomas: long term results. British Journal of Haematology, 2017, 178, 561-570.	1.2	12
183	Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. Clinical Lymphoma and Myeloma, 2009, 9, S261-S265.	1.4	11
184	Stem cell transplantation outcomes in lymphoblastic lymphoma. Leukemia and Lymphoma, 2017, 58, 366-371.	0.6	11
185	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer, 2017, 123, 3568-3575.	2.0	11
186	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged â‰¥75 years. Leukemia and Lymphoma, 2019, 60, 3536-3543.	0.6	11
187	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2019, 25, 1039-1044.	2.0	11
188	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplantation, 2021, 56, 2005-2012.	1.3	11
189	Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).. Blood, 2005, 106, 48-48.	0.6	11
190	Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood, 2013, 122, 691-691.	0.6	11
191	Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leukemia and Lymphoma, 2012, 53, 499-502.	0.6	10
192	Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy, 2014, 16, 1153-1157.	0.3	10
193	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clinical Cancer Research, 2019, 25, 6781-6787.	3.2	10
194	Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica, 2020, 106, 269-274.	1.7	10
195	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 1003.e1-1003.e13.	0.6	10
196	First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood, 2013, 122, 166-166.	0.6	10
197	Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplantation, 2014, 49, 1109-1112.	1.3	9
198	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. European Journal of Haematology, 2016, 97, 342-347.	1.1	9

#	Article	IF	Citations
199	Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplantation, 2018, 53, 315-325.	1.3	9
200	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Advances in Radiation Oncology, 2018, 3, 639-646.	0.6	9
201	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer, 2021, 127, 1598-1605.	2.0	9
202	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica, 2022, 107, 899-908.	1.7	9
203	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 3991-3991.	0.6	9
204	Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e105-e109.	0.2	8
205	Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood, 2017, 129, 3031-3033.	0.6	8
206	Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia and Lymphoma, 2016, 57, 2644-2652.	0.6	7
207	Longâ€term followâ€up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed Tâ€cell chimerism is associated with high relapse risk and inferior survival. British Journal of Haematology, 2017, 177, 567-577.	1.2	7
208	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1340-1346.	2.0	7
209	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61.	0.2	7
210	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Advances, 2020, 4, 1296-1306.	2.5	7
211	The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings. Current Hematologic Malignancy Reports, 2011, 6, 47-57.	1.2	6
212	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after highâ€dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion, 2017, 57, 1052-1057.	0.8	6
213	Predictors of inferior clinical outcome in patients with standardâ€risk multiple myeloma. European Journal of Haematology, 2017, 98, 263-268.	1.1	6
214	Outcomes of autologous stem cell transplantation in WaldenstrÃ¶mâ€™s macroglobulinemia. Annals of Hematology, 2019, 98, 2233-2235.	0.8	6
215	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy, 2021, 27, 913.e1-913.e12.	0.6	6
216	Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkinâ€™s Lymphomas.. Blood, 2004, 104, 2315-2315.	0.6	6

#	Article	IF	Citations
217	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. Blood, 2016, 128, 2270-2270.	0.6	6
218	Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Advances, 2022, 6, 2267-2274.	2.5	6
219	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 395.e1-395.e11.	0.6	6
220	Interleukin-2 and granulocyteâ€“macrophageâ€“colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. International Journal of Hematology, 2009, 90, 627-634.	0.7	5
221	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andÂSoft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1413-1417.	2.0	5
222	Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia Research, 2016, 47, 100-108.	0.4	5
223	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 36-42.	0.2	5
224	Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. American Journal of Hematology, 2019, 94, E176-E180.	2.0	5
225	Melphalanâ€based autologous transplant in octogenarian multiple myeloma patients. American Journal of Hematology, 2019, 94, E2-E5.	2.0	5
226	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1746-1749.	1.3	5
227	ZevalinÂ®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. Blood, 2007, 110, 620-620.	0.6	5
228	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood, 2012, 120, 4200-4200.	0.6	5
229	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood, 2013, 122, 410-410.	0.6	5
230	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood, 2015, 126, 854-854.	0.6	5
231	Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma After Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab. Leukemia and Lymphoma, 2003, 44, 829-832.	0.6	4
232	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia and Lymphoma, 2010, 51, 1478-1484.	0.6	4
233	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biology of Blood and Marrow Transplantation, 2015, 21, 1529-1531.	2.0	4
234	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leukemia and Lymphoma, 2018, 59, 515-518.	0.6	4

#	Article	IF	Citations
235	Longâ€term durable efficacy of autologous stem cell transplantation in POEMS syndrome. American Journal of Hematology, 2018, 94, E72-E74.	2.0	4
236	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1077-1083.	2.0	4
237	Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation. Pharmacotherapy, 2020, 40, 773-787.	1.2	4
238	Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplantation, 2021, 56, 745-748.	1.3	4
239	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. Blood, 2016, 128, 3554-3554.	0.6	4
240	Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.. Blood, 2005, 106, 1123-1123.	0.6	4
241	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. Blood, 2011, 118, 4118-4118.	0.6	4
242	Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and Cellular Therapy, 2022, 28, 501.e1-501.e7.	0.6	4
243	A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas. Journal of Blood Medicine, 2010, 1, 49.	0.7	3
244	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 1059-1063.	2.0	3
245	Epstein â€“ Barr virus specific cytotoxic T lymphocytes for the treatment of severe epsteinâ€barr virus mucocutaneous ulcer. British Journal of Haematology, 2020, 189, e33-e36.	1.2	3
246	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 404.e1-404.e5.	0.6	3
247	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensityâ€score matched analysis. American Journal of Hematology, 2021, 96, E455-E457.	2.0	3
248	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2005, 106, 1159-1159.	0.6	3
249	Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkinâ€™s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.. Blood, 2005, 106, 44-44.	0.6	3
250	Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.. Blood, 2006, 108, 2460-2460.	0.6	3
251	Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).. Blood, 2007, 110, 948-948.	0.6	3
252	Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood, 2014, 124, 1245-1245.	0.6	3

#	Article	IF	Citations
253	Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.. Journal of Clinical Oncology, 2013, 31, 7011-7011.	0.8	3
254	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfanâ€‰Â±â€‰clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	3
255	Diffuse Large B-cell Non-Hodgkinâ€™s Lymphoma Presenting as a Vaginal Mass in a Patient With a History of Intestinal Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 204-208.	0.6	2
256	Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S18-S22.	0.2	2
257	Donor Cellâ€“Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e151-e155.	0.2	2
258	Can we cure refractory Hodgkinâ€™s lymphoma with transplantation?. Bone Marrow Transplantation, 2021, 56, 278-281.	1.3	2
259	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica, 2021, 144, 74-81.	0.7	2
260	Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy, 2021, 23, 1029-1035.	0.3	2
261	Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation. European Journal of Haematology, 2021, 107, 634-641.	1.1	2
262	Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.. Blood, 2005, 106, 660-660.	0.6	2
263	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood, 2008, 112, 3320-3320.	0.6	2
264	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. Blood, 2009, 114, 868-868.	0.6	2
265	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4321-4321.	0.6	2
266	Efficacy of â€˜Off-the-Shelfâ€™, Commercially-Available, Third-Party Mesenchymal Stem Cells (MSC) in Ex Vivo Cord Blood (CB) Co-Culture Expansion.. Blood, 2007, 110, 4106-4106.	0.6	2
267	High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood, 2008, 112, 4452-4452.	0.6	2
268	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood, 2021, 138, 482-482.	0.6	2
269	Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. Biology of Blood and Marrow Transplantation, 2013, 19, S234-S235.	2.0	1
270	Granulocyte concentrates from a single high-yield apheresis can be split to support multiple patients. Leukemia and Lymphoma, 2014, 55, 2577-2583.	0.6	1

#	Article	IF	Citations
271	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Reports in Oncology, 2018, 11, 721-728.	0.3	1
272	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	0.6	1
273	Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.. Blood, 2004, 104, 734-734.	0.6	1
274	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2006, 108, 3090-3090.	0.6	1
275	Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkinâ€™s Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors.. Blood, 2006, 108, 3115-3115.	0.6	1
276	HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT).. Blood, 2006, 108, 3125-3125.	0.6	1
277	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2Rî³null (NSG) Mice as a Model.. Blood, 2009, 114, 2370-2370.	0.6	1
278	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2011, 118, 246-246.	0.6	1
279	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood, 2011, 118, 333-333.	0.6	1
280	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. Blood, 2012, 120, 3094-3094.	0.6	1
281	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5884-5884.	0.6	1
282	Allogeneic hematopoietic cell transplantation (alloHCT) in diffuse large B-cell lymphoma (DLBCL) after nonmyeloablative (NMA) or reduced-intensity (RIC) conditioning: Long-term outcome in 116 patients.. Journal of Clinical Oncology, 2013, 31, 8561-8561.	0.8	1
283	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. Blood, 2005, 106, 2923-2923.	0.6	1
284	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. Blood, 2007, 110, 3032-3032.	0.6	1
285	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood, 2008, 112, 2999-2999.	0.6	1
286	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. Blood, 2009, 114, 2310-2310.	0.6	1
287	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4354-4354.	0.6	1
288	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. Blood, 2012, 120, 3129-3129.	0.6	1

#	Article	IF	Citations
289	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	0.6	1
290	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020, 136, 17-18.	0.6	1
291	Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 29-30.	0.6	1
292	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood, 2020, 136, 9-10.	0.6	1
293	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 24-25.	0.6	1
294	Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Formative Research, 2022, 6, e29393.	0.7	1
295	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 307.e1-307.e8.	0.6	1
296	Hematopoietic stem cell transplantation for the management of follicular lymphoma. Stem Cells and Cloning: Advances and Applications, 2010, 3, 69.	2.3	0
297	Rhinovirus Infections (RhVI) in 233 Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
298	Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkinâ€™s Lymphomas.. Blood, 2004, 104, 2877-2877.	0.6	0
299	A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).. Blood, 2004, 104, 5184-5184.	0.6	0
300	Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.. Blood, 2004, 104, 3329-3329.	0.6	0
301	Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkinâ€™s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.. Blood, 2005, 106, 2902-2902.	0.6	0
302	Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.. Blood, 2005, 106, 2019-2019.	0.6	0
303	Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 5316-5316.	0.6	0
304	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkinâ€™s Lymphoma (NHL) in Patients over 65 Years of Age.. Blood, 2006, 108, 3059-3059.	0.6	0
305	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. Blood, 2006, 108, 5422-5422.	0.6	0
306	In Utero Is Superior to Ex Utero Cord Blood Collection.. Blood, 2006, 108, 3645-3645.	0.6	0

#	Article	IF	Citations
307	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. Blood, 2006, 108, 3101-3101.	0.6	0
308	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. Blood, 2007, 110, 5126-5126.	0.6	0
309	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkinâ€™s Lymphomas (NHLs).. Blood, 2007, 110, 1900-1900.	0.6	0
310	A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.. Blood, 2007, 110, 3051-3051.	0.6	0
311	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	0.6	0
312	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	0.6	0
313	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood, 2007, 110, 5015-5015.	0.6	0
314	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. Blood, 2008, 112, 1128-1128.	0.6	0
315	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood, 2008, 112, 3298-3298.	0.6	0
316	Foxp3 Expression Is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis. Blood, 2008, 112, 2912-2912.	0.6	0
317	Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood, 2008, 112, 3306-3306.	0.6	0
318	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 4326-4326.	0.6	0
319	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood, 2008, 112, 799-799.	0.6	0
320	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. Blood, 2009, 114, 3213-3213.	0.6	0
321	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.. Blood, 2009, 114, 2309-2309.	0.6	0
322	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.. Blood, 2009, 114, 1227-1227.	0.6	0
323	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood, 2010, 116, 3510-3510.	0.6	0
324	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood, 2010, 116, 2341-2341.	0.6	0

#	Article	IF	Citations
325	Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant.. Blood, 2010, 116, 1322-1322.	0.6	0
326	12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,. Blood, 2011, 118, 4138-4138.	0.6	0
327	Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2855-2855.	0.6	0
328	Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,. Blood, 2011, 118, 4047-4047.	0.6	0
329	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood, 2011, 118, 3106-3106.	0.6	0
330	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood, 2011, 118, 2006-2006.	0.6	0
331	Stem Cell Transplantation for Non-Hodgkinâ€™s Lymphomas. , 2013, , 371-402.		0
332	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	0.6	0
333	Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 2880-2880.	0.6	0
334	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. Journal of Clinical Oncology, 2014, 32, 8601-8601.	0.8	0
335	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8538-8538.	0.8	0
336	The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood, 2015, 126, 3984-3984.	0.6	0
337	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood, 2018, 132, 4607-4607.	0.6	0
338	Hematopoietic Stem Cell Transplantation for Rare Hematological Malignancies. , 2019, , 263-277.		0
339	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood, 2019, 134, 3596-3596.	0.6	0
340	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood, 2019, 134, 4598-4598.	0.6	0
341	The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. The Internet Journal of Hematology, 2009, 7, .	0.5	0
342	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood, 2021, 138, 1802-1802.	0.6	0

#	Article	IF	Citations
343	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 1779-1779.	0.6	0
344	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood, 2020, 136, 11-13.	0.6	0
345	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood, 2020, 136, 6-7.	0.6	0
346	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 18-19.	0.6	0
347	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
348	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
349	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-21.	0.6	0
350	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood, 2020, 136, 10-11.	0.6	0
351	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood, 2020, 136, 23-24.	0.6	0
352	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	0.6	0
353	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood, 2020, 136, 40-41.	0.6	0
354	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine Â± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2020, 136, 37-38.	0.6	0